Clinical Trial: Capecitabine in Treating Patients With Malignant Mesothelioma

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Capecitabine (Xeloda) in Malignant Mesothelioma: A Phase II Study

Brief Summary:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have malignant mesothelioma.

Detailed Summary:

OBJECTIVES: I. Determine the response rate, overall survival, and failure free survival of patients with malignant mesothelioma treated with capecitabine. II. Determine the toxicity of this regimen in these patients.

OUTLINE: This is a multicenter study. Patients receive oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 3 months for 2 years and then annually thereafter.

PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 7-9 months.

Sponsor: Alliance for Clinical Trials in Oncology

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Alliance for Clinical Trials in Oncology

Dates:
Date Received: January 21, 2000
Date Started: November 2000
Date Completion:
Last Updated: July 12, 2016
Last Verified: July 2016